APAR对肝细胞癌根治性切除术后患者预后的预测价值

doi:10.3877/cma.j.issn.2095-3232.2021.03.010

目的

探讨术前血清ALP和ALB比值（APAR）在肝细胞癌（HCC）根治性切除术后患者预后中的价值。

方法

回顾性分析2015年1月至2019年12月在川北医学院附属医院行根治性切除术的296例HCC患者临床资料。其中男257例，女39例；平均年龄（56±11）岁。患者均签署知情同意书，符合医学伦理学规定。采用ROC曲线确定APAR最佳界值。分析比较高APAR组和低APAR组临床病理学特征；分析APAR与患者术后生存的关系。生存分析采用Kaplan-Meier法和Log-rank检验。采用Cox比例风险回归模型分析HCC根治性切除术后患者预后的影响因素。

结果

根据APAR最佳界值3.38，将患者分为高APAR组（136例）和低APAR组（160例）。高APAR组患者术后1、3、5年无病生存率分别为49.4%、20.0%、5.1%，低APAR组相应为78.6%、42.7%、13.5%，低APAR组无病生存明显优于高APAR组（χ²=44.485，P<0.05）。Cox多因素分析显示，APAR≥3.38 U/g是影响HCC根治性切除术后患者无病生存的独立危险因素（HR=1.788，95%CI：1.241～2.577，P<0.05）。

结论

术前APAR是预测HCC根治性肝切除术后患者预后的独立影响因素，低APAR患者无病生存较佳。

关键词: 碱性磷酸酶, 白蛋白, 癌, 肝细胞, 肝切除术, 预后

Objective

To evaluate the prognostic value of preoperative serum alkaline phosphatase-to-albumin ratio (APAR) for patients with hepatocellular carcinoma (HCC) after radical hepatectomy.

Methods

Clinical data of 296 HCC patients who underwent radical hepatectomy in the Affiliated Hospital of North Sichuan Medical College from January 2015 to December 2019 were retrospectively analyzed. Among them, 257 patients were male and 39 female, aged (56±11) years on average. The informed consents of all patients were obtained and the local ethical committee approval was received. The optimal cut-off value of APAR was determined by the receiver operating characteristic (ROC) curve. The clinicopathological features of the high and low APAR groups were compared and the relationship between APAR and postoperative survival was analyzed. Survival analysis was performed by Kaplan-Meier method and Log-rank test. The prognostic factors of HCC patients after radical resection were identified by Cox's proportional hazards regression model.

Results

All patients were divided into the high APAR group (n=136) and low APAR group (n=160) according to the optimal cut-off value of APAR 3.38. The postoperative 1-, 3- and 5-year disease-free survival in high APAR group were 49.4%, 20.0%, and 5.1%, respectively and were 78.6%, 42.7%, 13.5% in low APAR group, the disease-free survival in low APAR group was significantly better than that in high APAR group (χ²=44.485, P<0.05). Cox's multivariate analysis showed that APAR≥3.38 U/g wasan independent risk factor for the disease-free survival of HCC patients after radical resection (HR=1.788, 95%CI: 1.241-2.577, P<0.05).

Conclusions

Preoperative APAR is an independent prognostic factor for HCC patients after radical hepatectomy. Patients with low APAR have better disease-free survival than those with high APAR.

Key words: Alkaline phosphatase, Albumin, Carcinoma, hepatocellular, Hepatectomy, Prognosis

图1 APAR评估HCC根治性切除术后患者生存情况的ROC曲线

表1 高APAR组和低APAR组HCC根治性切除术患者临床病理特征比较

临床特征	例数	GGT[U/L，M（Q_R）]	ALT[U/L，M（Q_R）]	AST[U/L，M（Q_R）]	TB[μmol/L，M（Q_R）]	最大肿瘤直径[cm，M（Q_R）]
高APAR组	136	95（156）	60（74）	58（71）	18（10）	7.0（6）
低APAR组	160	63（105）	50（46）	50（53）	16（10）	4.5（3）
统计值		Z=2.998	Z=2.307	Z=2.338	Z=0.770	Z=4.789
P值		<0.05	<0.05	<0.05	0.441	<0.05
临床特征	例数	肝硬化（例）		大血管侵犯（例）		BCLC分期（例）		肿瘤复发（例）
临床特征	例数	有	无	有	无	0+A期	B期	有	无
高APAR组	136	109	27	81	55	78	58	96	40
低APAR组	160	99	61	36	124	124	36	61	99
统计值		χ²=11.748		χ²=42.237		χ²=13.769		χ²=31.104
P值		<0.05		<0.05		<0.05		<0.05

表1 高APAR组和低APAR组HCC根治性切除术患者临床病理特征比较

临床特征	例数	GGT[U/L，M（Q_R）]	ALT[U/L，M（Q_R）]	AST[U/L，M（Q_R）]	TB[μmol/L，M（Q_R）]	最大肿瘤直径[cm，M（Q_R）]
高APAR组	136	95（156）	60（74）	58（71）	18（10）	7.0（6）
低APAR组	160	63（105）	50（46）	50（53）	16（10）	4.5（3）
统计值		Z=2.998	Z=2.307	Z=2.338	Z=0.770	Z=4.789
P值		<0.05	<0.05	<0.05	0.441	<0.05
临床特征	例数	肝硬化（例）		大血管侵犯（例）		BCLC分期（例）		肿瘤复发（例）
临床特征	例数	有	无	有	无	0+A期	B期	有	无
高APAR组	136	109	27	81	55	78	58	96	40
低APAR组	160	99	61	36	124	124	36	61	99
统计值		χ²=11.748		χ²=42.237		χ²=13.769		χ²=31.104
P值		<0.05		<0.05		<0.05		<0.05

图2 高、低APAR组HCC根治性切除术后患者无病生存Kaplan-Meier曲线

表2 HCC根治性切除术后患者预后的Cox单因素及多因素分析

临床特征	单因素分析		多因素分析
	HR（95%CI）	P值	HR（95%CI）	P值
肿瘤最大直径>7 cm	1.201（1.150～1.255）	<0.05	1.104（1.045～1.167）	<0.05
肿瘤数量≥3个	1.443（1.031～2.021）	<0.05	1.446（1.029～2.034）	<0.05
肝硬化	1.934（1.299～2.879）	<0.05	1.672（1.110～2.518）	<0.05
大血管侵犯	1.637（1.195～2.242）	<0.05	1.035（0.735～1.458）	0.844
BCLC-B期	0.289（0.210～0.397）	<0.05	0.454（0.312～0.660）	<0.05
APAR≥3.38 U/g	2.655（1.924～3.665）	<0.05	1.788（1.241～2.577）	<0.05

表2 HCC根治性切除术后患者预后的Cox单因素及多因素分析

临床特征	单因素分析		多因素分析
	HR（95%CI）	P值	HR（95%CI）	P值
肿瘤最大直径>7 cm	1.201（1.150～1.255）	<0.05	1.104（1.045～1.167）	<0.05
肿瘤数量≥3个	1.443（1.031～2.021）	<0.05	1.446（1.029～2.034）	<0.05
肝硬化	1.934（1.299～2.879）	<0.05	1.672（1.110～2.518）	<0.05
大血管侵犯	1.637（1.195～2.242）	<0.05	1.035（0.735～1.458）	0.844
BCLC-B期	0.289（0.210～0.397）	<0.05	0.454（0.312～0.660）	<0.05
APAR≥3.38 U/g	2.655（1.924～3.665）	<0.05	1.788（1.241～2.577）	<0.05

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2]	Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge[J]. Hepatology, 2011, 54(3):757-759.
[3]	Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update[J]. Hepatol Int, 2017,11(4):317-370.
[4]	Pu N, Gao S, Xu Y, et al. Alkaline phosphatase-to-albumin ratio as a prognostic indicator in pancreatic ductal adenocarcinoma after curative resection[J]. J Cancer, 2017, 8(16):3362-3370.
[5]	Zhou W, Fang Y, Han X, et al. The value of alkaline phosphatase-to-albumin ratio in detecting synchronous metastases and predicting postoperative relapses among patients with well-differentiated pancreatic neuroendocrine neoplasms[J]. J Oncol, 2020: 8927531.
[6]	Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822): 1245-1255.
[7]	Chun YH, Kim SU, Park JY, et al. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma[J]. Eur J Cancer, 2011, 47(17):2568-2575.
[8]	Poupon R. Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation[J]. Hepatology, 2015, 61(6): 2080-2090.
[9]	Epstein E, Kiechle FL, Artiss JD, et al. The clinical use of alkaline phosphatase enzymes[J]. Clin Lab Med, 1986, 6(3):491-505.
[10]	Usoro NI, Omabbe MC, Usoro CA, et al. Calcium, inorganic phosphates, alkaline and acid phosphatase activities in breast cancer patients in Calabar, Nigeria[J]. Afr Health Sci, 2010, 10(1):9-13.
[11]	Namikawa T, Ishida N, Tsuda S, et al. Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer[J]. Gastric Cancer, 2019, 22(4):684-691.
[12]	Li D, Lv H, Hao X, et al. Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis[J]. Cancer Manag Res, 2018(10):3125-3139.
[13]	Xu XS, Wan Y, Song SD, et al. Model based on γ-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis[J]. World J Gastroenterol, 2014, 20(31):10944-10952.
[14]	Yu MC, Chan KM, Lee CF, et al. Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence?[J]. J Gastrointest Surg, 2011, 15(8):1440-1449.
[15]	Nojiri S, Joh T. Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle[J]. Int J Mol Sci, 2014, 15(3):5163-5174.
[16]	Garcia-Martinez R, Andreola F, Mehta G, et al. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure[J]. J Hepatol, 2015, 62(4):799-806.
[17]	Seaton K. Albumin concentration controls cancer[J]. J Natl Med Assoc, 2001, 93(12):490-493.
[18]	Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis[J]. J Hepatol, 2014, 61(2):396-407.
[19]	Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature[J]. Nutr J, 2010(9):69.
[20]	Heys SD, Walker LG, Deehan DJ, et al. Serum albumin: a prognostic indicator in patients with colorectal cancer[J]. J R Coll Surg Edinb, 1998, 43(3):163-168.
[21]	Yamashita K, Ushiku H, Katada N, et al. Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test[J]. Eur J Surg Oncol, 2015, 41(10):1324-1332.
[22]	Wu N, Chen G, Hu H, et al. Low pretherapeutic serum albumin as a risk factor for poor outcome in esophageal squamous cell carcinomas[J]. Nutr Cancer, 2015, 67(3):481-485.
[23]	Gion T, Taketomi A, Shimada M, et al. Perioperative change in albumin messenger RNA levels in patients with hepatocellular carcinoma[J]. Hepatology, 1998, 28(6):1663-1668.
[24]	Chi KN, Kheoh T, Ryan CJ, et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel[J]. Ann Oncol, 2016, 27(3):454-460.
[25]	李金亭，王俊丽，傅山岗, 等. 大鼠肝再生过程中碱性磷酸酶活性变化及其超微细胞化学研究[J]. 解剖学报, 2004, 35(4):392-395.
[26]	Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients[J]. N Engl J Med, 2000, 342(17):1266-1271.
[27]	Esper DH, Harb WA. The cancer cachexia syndrome: a review of metabolic and clinical manifestations[J]. Nutr Clin Pract, 2005, 20(4):369-376.
[28]	Kamiyama T, Nakanishi K, Yokoo H, et al. Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma[J]. World J Surg Oncol, 2012(10):107.
[29]	Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J]. J Hepatol, 2003, 38(2):200-207.
[30]	Yamamoto Y, Ikoma H, Morimura R, et al. Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy[J]. World J Gastroenterol, 2015, 21(4):1207-1215.
[31]	Giannini EG, Farinati F, Ciccarese F, et al. Prognosis of untreated hepatocellular carcinoma[J]. Hepatology, 2015, 61(1):184-190.
[32]	Regimbeau JM, Abdalla EK, Vauthey JN, et al. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study[J]. J Surg Oncol, 2004, 85(1):36-41.

[1]	燕速, 霍博文. 腹腔镜食管胃结合部腺癌根治性切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 13-13.
[2]	李子禹, 卢信星, 李双喜, 陕飞. 食管胃结合部腺癌腹腔镜手术重建方式的选择[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 5-8.
[3]	李乐平, 张荣华, 商亮. 腹腔镜食管胃结合部腺癌根治淋巴结清扫策略[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 9-12.
[4]	许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[5]	李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[6]	李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[7]	常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[8]	高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[9]	李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[10]	冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[11]	陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[12]	郭兵, 王万里, 何凯, 黄汉生. 腹腔镜下肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 143-143.
[13]	魏丽霞, 张安澜, 周宝勇, 李明. 腹腔镜下Ⅲb型肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 145-145.
[14]	王湛, 李文坤, 杨奕, 徐芳, 周敏思, 苏珈仪, 王亚丹, 吴静. 炎症指标在早发性结直肠肿瘤中的应用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 802-810.
[15]	刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Prognostic value of APAR for patients with hepatocellular carcinoma after radical hepatectomy

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Prognostic value of APAR for patients with hepatocellular carcinoma after radical hepatectomy